Vomibull 2mg Syrup 30ml

Side Effects of Vomibull 2mg Syrup 30ml

Headache, hiccups, flushing or warmth sensation, constipation, rash, urticaria; seizures and movement disorders including extrapyramidal symptoms (e.g. dyskinesia, dystonia, oculogyric crisis). IV: Inj site reaction, dizziness, transient visual disturbances (blurred vision or very rarely, transient blindness). Supp: Local burning sensation; transient liver enzyme elevation. Rarely, anaphylaxis, bradycardia and tachycardia, arrhythmia, chest pain, hypotension, transient ECG changes. Potentially Fatal: Torsade de pointes, anaphylaxis.

Drug Interactions

May reduce analgesic effect of tramadol. Rifampicin and other CYP3A4 inducers may reduce levels/effects of ondansetron. Concomitant use of QT-prolonging agents (e.g. antiarrhythmics) may cause additive prolongation of QT interval. May increase the risk of arrhythmias w/ cardiotoxic drugs (e.g. anthracyclines). Potentially Fatal: May increase the hypotensive effect of apomorphine.

Contraindications

Patients w/ congenital long QT syndrome. Concomitant use of apomorphine.

Mechanism of Action

Ondansetron antagonises selective 5-HT3-receptor, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. This action of ondansetron gives it its antiemetic property to prevent emesis due to acute chemotherapy mediated by serotonin. Onset: Approx 30 min. Absorption: Well absorbed from the GI tract (oral). Absolute bioavailability: Approx 60%. Time to peak plasma concentration: Oral: Approx 1.5 hr; rectal: Approx 6 hr. Distribution: Widely distributed. Plasma protein binding: Approx 70-75%. Metabolism: Extensively hepatic via hydroxylation, followed by sulfate or glucuronide conjugation which involves CYP3A4, CYP1A2 and CYP2D6 isoenzymes. Demethylation may also occur. Excretion: Via urine (44-60% as metabolites; approx 5% as unchanged drug), faeces (approx 25%). Terminal elimination half-life: Oral/parenteral: Approx 3 hr; rectal: Approx 6 hr.

Special Precautions

May mask progressive ileus and/or gastric distension. Severe hepatic impairment. Pregnancy and lactation. Monitoring Parameters ECG monitoring of patients w/ electrolytes abnormalities e.g. hypomagnesaemia or hypokalaemia, CHF or bradyarrhythmias and on medication that can prolong QT interval.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.